# Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)

> **NCT01242774** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 46 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Panobinostat

## Key facts

- **NCT ID:** NCT01242774
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01242774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01242774, "Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01242774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*